Skip to main content

1 Result(s)

within English Remove this filter Biomedicine, general Remove this filter Epidemiology Remove this filter Kana Akiyama Remove this filter

and

  1. No Access

    Article

    Dexamethasone-sparing on days 2–4 with combined palonosetron, neurokinin-1 receptor antagonist, and olanzapine in cisplatin: a randomized phase III trial (SPARED Trial)

    This study evaluated the non-inferiority of dexamethasone (DEX) on day 1, with sparing on days 2–4 in cisplatin-based chemotherapy.

    Hiroko Minatogawa, Naoki Izawa, Kazuhiro Shimomura… in British Journal of Cancer (2024)